Health and Healthcare
Stem Cell Stocks Take Off (ASTM, GERN, OPXA, STEM)
Published:
Last Updated:
Tickerspy’s Stem Cell Stock Index (*RSXTM) took off today, rising nearly 13%. The movement followed a release from the National Institutes of Health (NIH) announcing that 13 embryonic stem cell lines were approved for funding.
Opexa Therapeutics Inc (NASDAQ: OPXA) led the rise in stem cell stocks, surging over 40%. The company seeks to develop treatments to major illnesses, such as multiple sclerosis and diabetes, through stem cell research. The company’s stock has risen 2837% off its lows for the year.
StemCells Inc (NASDAQ: STEM) rose over 30% to a high of $1.45. The company engages in research aimed at developing treatment for organ damage using stem cells. The company’s stock is up over 1544% off its low for the year.
Garrett W. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
